What are the available package sizes?

Available sizes include 100ml, 250ml, 500ml, and 1000ml.

What are the payment terms?

Payment terms include LC and T/T.

What is the lead time for orders?

The average lead time is one month during peak season.

Soft Bag Ringer Lactate Injection Medicine Infusion

Name: Soft Bag Ringer Lactate Injection Medicine Infusion
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 1959431401

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.23

30,000 Pieces

Sample price:US$5.00/piece.Request sample

Product profile

Customization

Available

Application

Infusion Product

Usage Mode

Infusion Product

Model NO.

Ringer Lactate//Hartmann's Injection 500ML bottle

Suitable for

Elderly, Children, Adult

State

Liquid

Shape

Infusion Product

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Transport Package

30bags/Carton

Specification

500ML

Trademark

SHIMEN

Origin

China

HS Code

300490

Production Capacity

1billion/Year

Key features

Comprehensive Electrolyte Balance: Corrects metabolic acid toxicosis and dehydration by adjusting electrolyte and acid-alkali equilibrium.

Multi-Species Application: Suitable for elderly, adults, and children requiring intravenous infusion therapy.

GMP Certified Manufacturing: Produced by Shijiazhuang No.4 Pharmaceutical Co., Ltd. with SFDA GMP approval.

High Production Capacity: Yearly output exceeds 1200 million bottles, including 40 million soft plastic bottles.

Global Market Reach: Products exported to South America, Africa, Asia, Oceania, and the Middle East.

Flexible Packaging Options: Available in 100ml, 250ml, 500ml, and 1000ml soft plastic bottle formats.

Established Manufacturer: Company established in 1948 with over 3000 employees and USD 58 million capital.

Clear Liquid Formulation: Colorless clear liquid containing sodium lactate, sodium chloride, potassium chloride, and calcium chloride.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤24hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.